Dabrafenib plus trametinib improves relapse-free survival time in melanoma

Source: Healio, February 2021

Patients with a stage III melanoma mutation treated with dabrafenib plus trametinib had longer restricted mean survival times compared with placebo, according to an analysis of a phase 3 trial presented at Maui Derm for Dermatologists.

“Kaplan-Meier and Cox regression analyses have been used to assess adjuvant treatment effects based on time-to-event analyses,” John M. Kirkwood, MD, and colleagues wrote in the poster. “Unfortunately, these statistical methods do not account for nonproportional hazards and the fact that some patients never experience relapse.”

READ THE ORIGINAL FULL ARTICLE